North America Leukemia Therapeutics Market

North America Leukemia Therapeutics Market Size, Share & Industry Trends Analysis Report By Drug Class (Targeted Therapy & Immunotherapy and Chemotherapy), By Distribution Channel, By Type, By Country and Growth Forecast, 2023 - 2029

Report Id: KBV-15530 Publication Date: May-2023 Number of Pages: 96
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support

Market Report Description

The North America Leukemia Therapeutics Market would witness market growth of 5.4% CAGR during the forecast period (2023-2029).

Leukemia is a specific type of blood cancer that is characterized by abnormal leukocyte cell proliferation. Either acute or chronic leukemia is the classification. When the DNA in blood cells termed leukocytes mutates or changes, it impairs the cells' capacity to regulate growth and division. Sometimes, these immune system-evading mutant cells proliferate unchecked and crowd out healthy blood cells. Adults over 55 are most likely to experience it.

Bleeding, bone pain, brushing, exhaustion, and fever are just a few of the symptoms that arise from a lack of healthy blood cells. Additionally, the treatment may combine targeted therapy, chemotherapy, and immunotherapy, depending on the needs of the patient. The need for better treatments that can enhance patient outcomes is growing as leukemia continues to be a major health concern.

Tyrosine kinase inhibitors (TKIs), which focus on particular genes or proteins implicated in leukemia cell proliferation and spread, have been developed as a result of this. More people are becoming aware of leukemia and the need for effective therapies, which has increased demand for leukemia medications including chemotherapy and targeted therapy pharmaceuticals. The regional increase in healthcare spending is also a major factor in the market's expansion. Targeted therapies are becoming more and more in demand as a result of the increased emphasis on customized care and the development of new diagnostic techniques.

Approximately 1 million new cancer cases were reported in the United States in 2019, and 599,589 people died from the disease, according to data released by the Centers for Disease Control and Prevention (CDC). For every 100,000 persons in the country, 439 new cancer cases were reported, 146 of whom died. According to the Canadian Government's Cancer Statistics, 43% of Canadian women and 45% of Canadian men will develop cancer during their lifetime. There will be an increase in the number of new cancer patients as Canada's population ages and grows. Many deaths in Canada are primarily caused by cancer. As a result, there will be significant investment prospects for the major market players in the regional market as the number of cancer patients rises.

The US market dominated the North America Leukemia Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $3,338.3 million by 2029. The Canada market is poised to grow at a CAGR of 7.8% during (2023 - 2029). Additionally, The Mexico market would witness a CAGR of 6.8% during (2023 - 2029).

Based on Drug Class, the market is segmented into Targeted Therapy & Immunotherapy and Chemotherapy. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Providers. Based on Type, the market is segmented into Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Acute Myeloid Leukemia and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

Free Valuable Insights: The Worldwide Leukemia Therapeutics Market is Projected to reach USD 11.7 Billion by 2029, at a CAGR of 6%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Gilead Sciences, Inc., Bristol Myers Squibb Company, Sanofi S.A., AbbVie, Inc., Teva Pharmaceuticals Industries Ltd., Lupin Limited, Amgen, Inc., Takeda Pharmaceutical Company Limited, Pfizer, Inc. and Novartis AG.

Scope of the Study

Market Segments Covered in the Report:

By Drug Class

  • Targeted Therapy & Immunotherapy
  • Chemotherapy

By Distribution Channel

  • Hospital Pharmacies
  • Drug Store & Retail Pharmacies
  • Online Providers

By Type

  • Chronic Lymphocytic Leukemia
  • Acute Lymphocytic Leukemia
  • Chronic Myeloid Leukemia
  • Acute Myeloid Leukemia
  • Others

By Country

  • US
  • Canada
  • Mexico
  • Rest of North America

Key Market Players

List of Companies Profiled in the Report:

  • Gilead Sciences, Inc.
  • Bristol Myers Squibb Company
  • Sanofi S.A.
  • AbbVie, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Lupin Limited
  • Amgen, Inc.
  • Takeda Pharmaceutical Company Limited
  • Pfizer, Inc.
  • Novartis AG
Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now


Call: +1(646) 600-5072


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo